Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy

Clinical Infectious Diseases

Volumn 51, Issue 4, 2010, Pages 371-378

  Fitzwater, Sean P ^a   Caviedes, Luz ^a,c   Gilman, Robert H ^a,c,d,g   Coronel, Jorge ^c   LaChira, Doris ^e   Salazar, Cayo ^e   Saravia, Juan Carlos ^f   Reddy, Krishna ^b,c   Friedland, Jon S ^g   Moore, David A J ^a,c,d,g,h  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d ASOCIACIÓN BENÉFICA PRISMA   (Peru)

^e Direccion de Salud IV Lima Este   (Peru)

^f MINISTERIO DE SALUD   (Peru)

^g Wellcome Centre for Clinical Tropical Medicine   (United Kingdom)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AURAMINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM CULTURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERU; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SHORT COURSE THERAPY; SPUTUM SMEAR; TUBERCULOSIS; ANIMAL; BACTERIAL SHEDDING; COHORT ANALYSIS; DIRECTLY OBSERVED THERAPY; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MICROSCOPY; MIDDLE AGED; SPUTUM; TIME; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL SHEDDING; BACTERIOLOGICAL TECHNIQUES; COHORT STUDIES; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PERU; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 77955689295     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655127     Document Type: Article

References (33)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report 2008. Report WHO/HTM/TB/ 2008.393. Geneva, Switzerland: World Health Organization, 2008.
2. Stop TB Partnership, World Health Organization. Global plan to stop TB 2006-2015. Report WHO/HTM/STB/2006.35. Geneva, Switzerland: World Health Organization, 2006.
3. The effect of tuberculosis control in China. Lancet 2004; 364:417-422.
4. Suarez PG, Watt CJ, Alarcon E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis 2001; 184:473-478.
5. Huong NT, Duong BD, Co NV, et al. Tuberculosis epidemiology in six provinces of Vietnam after the introduction of the DOTS strategy. Int J Tuberc Lung Dis 2006; 10:963-969.
6. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006; 42:1040-1047.
7. Behr MA,Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353:444-449.
8. Hernandez-Garduno E, Cook V, Kunimoto D, Elwood RK, Black WA, FitzGerald J.M. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax 2004; 59:286-290.
9. Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007; 11:485-495.
10. World Health Organization. The global MDR-TB & XDR-TB response plan 2007-2008. Report WHO/HTM/TB/2007.387. Geneva, Switzerland: World Health Organization, 2007.
11. Bonilla CA, Crossa A, Jave HO, et al. Management of extensively drugresistant tuberculosis in Peru: cure is possible. PLoSONE2008; 3:e2957.
12. World Health Organization. Anti-tuberculosis drug resistance in the world, fourth global report. Report WHO/HTM/TB/2008.394. Geneva, Switzerland: World Health Organization, 2008.
13. World Health Organization. Report on Conclusions and Recommendations of the Strategic and Technical Advisory Group for Tuberculosis, Seventh Meeting. Geneva, Switzerland:World Health Organization, 2007.
14. Clinical diagnosis and management of tuberculosis and measures for its prevention and control. London, UK: National Institute for Health and Clinical Excellence, 2006.
15. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976; 57:275-299.
16. Escombe AR, Oeser C, Gilman RH, et al. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin Infect Dis 2007; 44:1349-1357.
17. Menzies D. Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Infect Control Hosp Epidemiol 1997; 18:582-586.
18. Riley RL, Mills CC, O'Grady F, Sultan LU, Wittstadt F, Shivpuri D.N. Infectiousness of air from a tuberculosis ward: ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 1962; 85:511-525.
19. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drugsusceptibility assay for the diagnosis of T.B. N Engl J Med 2006; 355:1539-1550.
20. World Health Organization. Laboratory services in TB control, parts I, II, and II.I. Report WHO/tb/98.258. Geneva, Switzerland:WorldHealth Organization, 1998.
21. Barreto AM, Araujo JB, de Melo Medeiros RF, de Souza Caldas P.C. Evaluation of indirect susceptibility testing of Mycobacterium tuberculosis to the first- and second-line, and alternative drugs by the newer MB/BacT system. Mem Inst Oswaldo Cruz 2003; 98:827-830.
22. YewWW, Tong SC, Lui KS, Leung SK, Chau CH,Wang EP. Comparison of MB/BacT system and agar proportion method in drug susceptibility testing of Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2001; 39:229-232.
23. Caviedes L, Lee TS, Gilman RH, et al.; The TuberculosisWorking Group in Peru. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. J Clin Microbiol 2000; 38:1203-1208.
24. Moore DA, Mendoza D, Gilman RH, et al. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrugresistant tuberculosis suitable for use in resource-poor settings. J Clin Microbiol 2004; 42:4432-4437.
25. Franzblau SG, Witzig RS, McLaughlin JC, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 1998; 36: 362-366.
26. Fortun J, Martin-Davila P, Molina A, et al. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J Antimicrob Chemother 2007; 59:794-798.
27. Long R, Bochar K, Chomyc S, et al. Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment. Infect Control Hosp Epidemiol 2003; 24:831-838.
28. Kawai V, Soto G, Gilman RH, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg 2006; 75:1027-1033.
29. Telzak EE, Fazal BA, Pollard CL, Turett GS, Justman JE, Blum S. Factors influencing time to sputum conversion among patients with smearpositive pulmonary tuberculosis. Clin Infect Dis 1997; 25:666-670.
30. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione M.C. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 2002; 6:858-864.
31. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, Mitnick C.D. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004; 8:52-58.
32. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537-2545.
33. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.